Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Share-based Compensation: 2016-2024

Historic Share-based Compensation for Krystal Biotech (KRYS) over the last 9 years, with Dec 2024 value amounting to $49.1 million.

  • Krystal Biotech's Share-based Compensation fell 1.22% to $13.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $54.1 million, marking a year-over-year increase of 18.59%. This contributed to the annual value of $49.1 million for FY2024, which is 23.02% up from last year.
  • Per Krystal Biotech's latest filing, its Share-based Compensation stood at $49.1 million for FY2024, which was up 23.02% from $39.9 million recorded in FY2023.
  • In the past 5 years, Krystal Biotech's Share-based Compensation registered a high of $49.1 million during FY2024, and its lowest value of $3.3 million during FY2020.
  • Moreover, its 3-year median value for Share-based Compensation was $39.9 million (2023), whereas its average is $40.8 million.
  • Data for Krystal Biotech's Share-based Compensation shows a peak YoY skyrocketed of 368.18% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Krystal Biotech's Share-based Compensation stood at $3.3 million in 2020, then skyrocketed by 368.18% to $15.3 million in 2021, then spiked by 116.92% to $33.2 million in 2022, then rose by 20.17% to $39.9 million in 2023, then rose by 23.02% to $49.1 million in 2024.